SCHEMBL19209070

SCHEMBL19209070

O=C(C=P(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccc(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.50
MAOB P27338 4/20 0.49
MAPT P10636 2/20 0.49
HTT P42858 2/20 0.49
ALDH1A1 P00352 1/20 0.49
GAA P10253 1/20 0.49
HPGD P15428 1/20 0.49
PARP1 P09874 1/20 0.47
KCNK3 O14649 1/20 0.45
KCNK9 Q9NPC2 1/20 0.45
MAOA P21397 3/20 0.44
PTPN1 P18031 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
ERCC5 P28715 1/20 0.44
FEN1 P39748 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TGM2 P21980 1/20 0.43
CYP1A1 P04798 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19033787 0.82 HSP90AA1 (0.63) HSP90AA1MAOBMAPTHTTALDH1A1
SCHEMBL977997 0.82 HSP90AA1 (0.63) HSP90AA1MAOBMAPTHTTALDH1A1
SCHEMBL9539946 0.81 HSP90AA1 (0.54) HSP90AA1MAOBMAPTHTTALDH1A1
SCHEMBL20677795 0.80 NPC1 (0.49) HSP90AA1MAPTALDH1A1GAANPC1
SCHEMBL19243172 0.77 MAOB (0.59) HSP90AA1MAOBMAPTHTTALDH1A1
SCHEMBL20677800 0.77 MAOB (0.59) MAOBMAPTHTTALDH1A1GAA
SCHEMBL19243169 0.75 MEN1 (0.57) HSP90AA1MAPTALDH1A1HPGDPTPN1
SCHEMBL31167601 0.75 ALDH1A1 (0.71) MAOBMAPTHTTALDH1A1GAA
SCHEMBL14855431 0.75 MAOB (0.61) MAOBMAPTHTTALDH1A1GAA
SCHEMBL20677772 0.74 HSP90AA1 (0.58) HSP90AA1ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190031665-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER EMCURE PHARMACEUTICALS LIMITED (IN) 2019-01-31 US disclosed
US-20190031665-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER EMCURE PHARMACEUTICALS LIMITED (IN) 2019-01-31 US disclosed
EP-3400226-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER Emcure Pharmaceuticals Limited (IN) 2018-11-14 EP disclosed
WO-2017134555-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER EMCURE PHARMACEUTICALS LIMITED (IN) 2017-08-10 WO disclosed
WO-2017134555-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER EMCURE PHARMACEUTICALS LIMITED (IN) 2017-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190031665-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER IDO1, IDO2, TDO2 HSP90AA1 3424/4885MAOB 21/4885MAPT 3786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.